
Wave Life Sciences (WVE) shares crashed more than 50% on Mardh 26 after the company’s interim Phase 1 data for its obesity candidate WVE-007 disappointed investors.
This immense pressure on Thursday saw WVE’s relative strength index (14-day) slip below 20, indicating extremely oversold conditions that often trigger a relief rally.